Chemo-Immunotherapy May Have Edge in Advanced NSCLC With Hig

The analysis used data from studies of patients with advanced NSCLC and a PD-L1 tumor proportion score of 50% or higher treated in the first-line setting with either combination chemotherapy and immunotherapy, or immunotherapy alone.

Related Keywords

Silver Spring , Maryland , United States , Oladimeji Akinboro , Drug Administration In Silver Spring , Drug Evaluation , Drug Administration ,